Index by author

January 01, 2012; Volume 79,Issue 1

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Nicholls, Stephen J.
1. You have access
  Is niacin ineffective? Or did AIM-HIGH miss its target?
  Stephen J. Nicholls, MBBS, PhD
  
  Cleveland Clinic Journal of Medicine January 2012, 79 (1) 38-43; DOI: https://doi.org/10.3949/ccjm.79a.11166
  
  The AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) found, in an interim analysis, no cardiovascular benefit from taking extended-release niacin (Niaspan). In fact, there was a trend toward a greater risk of ischemic stroke, which did not reach statistical significance. But questions remain about this complex trial, which included intensive statin therapy in the active-treatment group and the control group.